Compare · HOOK vs OYST
HOOK vs OYST
Side-by-side comparison of HOOKIPA Pharma Inc. (HOOK) and Oyster Point Pharma Inc. (OYST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HOOK and OYST operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- OYST is the larger of the two at $306.1M, about 7.5x HOOK ($41.0M).
- HOOK has more recent analyst coverage (11 ratings vs 3 for OYST).
- Company
- HOOKIPA Pharma Inc.
- Oyster Point Pharma Inc.
- Price
- $0.87-3.61%
- $11.16+0.00%
- Market cap
- $41.0M
- $306.1M
- 1M return
- +0.00%
- -
- 1Y return
- -8.41%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2019
- News (4w)
- 0
- 0
- Recent ratings
- 11
- 3
HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Oyster Point Pharma Inc.
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Latest HOOK
- HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
- Chief Executive Officer Peters Malte sold $20,684 worth of shares (25,172 units at $0.82), decreasing direct ownership by 32% to 54,347 units (SEC Form 4)
- SEC Form 15-12G filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form 25 filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.
Latest OYST
- Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
- SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form 15-12G filed by Oyster Point Pharma Inc.
- Oyster Point Pharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits (Amendment)
- SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form EFFECT filed by Oyster Point Pharma Inc.
- SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form 4 filed by Invopps Gp Iv, L.L.C.